{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:31:12Z","timestamp":1767907872225,"version":"3.49.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>The thyroid peroxidase inhibiting compounds methimazole, methylthiouracil, propylthiouracil, thiouracil (i.e. \u2018antithyroid\u2019 drugs) and ethylenethiourea have been associated to thyroid tumours in rodents. According to a systematic review by the International Agency for Research on Cancer (IARC) published in 2000, evidence for the human carcinogenicity was inadequate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed an up-to-date systematic review of human epidemiological studies on the association between such compounds and thyroid cancer incidence or mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The literature research (1999\u2013March 2020) identified four relevant articles. Considering also reports from the previous IARC review, this systematic review considered seven reports (five distinct studies) on antithyroid drugs and two on ethylenethiourea. As for antithyroid drugs, three reports based on different follow-ups gave results from a cohort of patients treated for hyperthyroidism in 1946\u20131964. In the earlier report, thyroid cancer incidence was higher in patients primarily treated with antithyroid drugs (3.2\/1000) than in those originally treated with thyroidectomy (0.34\/1000) or radioactive iodine (0.88\/1000), which can be explained by the higher frequency of subsequent thyroidectomy, and hence the higher chance of cancer detection, in that group (30 vs. 0.5 and 1.2%). The two subsequent reports found no deaths from thyroid cancer among patients treated exclusively with antithyroid drugs through 1990 and 2014. A nested case-control study found an odds ratio (OR) of thyroid cancer of 2.79 [95% confidence interval (CI), 0.78\u201310.02, from a 2-year lag analysis] for \u22653 vs. no propylthiouracil prescriptions. The increased risk can be attributed to advanced diagnosis of an underlying cancer, as suggested by the stronger association observed in a no-lag analysis (OR, 8.03). In a historical cohort of newly diagnosed hyperthyroid patients, the hazard ratio for treatment with radioactive iodine vs. thionamides only was 0.45 (95% CI, 0.21\u20130.99), possibly due to the closer surveillance of patients receiving thionamides only. Two case-control studies did not find any association with the use of antithyroid drugs. As for ethylenethiourea, no thyroid cancer cases were found in a historical cohort of 1929 workers occupationally exposed in a 15-year period and no association with proxies of mancozeb exposure (a fungicide whose main metabolite is ethylenethiourea) was detected in a cohort of &gt;236\u2009000 farmers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>There is no evidence for a relevant role of either antithyroid drugs or ethylenethiourea on thyroid cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cej.0000000000000658","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T01:03:25Z","timestamp":1611536605000},"page":"64-72","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Exposure to antithyroid drugs and ethylenethiourea and risk of thyroid cancer: a systematic review of the epidemiologic evidence"],"prefix":"10.1097","volume":"31","author":[{"given":"Carlo","family":"La Vecchia","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Turati","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics and Biometry, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Negri","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"e1002742","DOI":"10.1371\/journal.pmed.1002742","article-title":"COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology.","volume":"16","author":"Dekkers","year":"2019","journal-title":"Plos Med"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jcem-38-6-976","article-title":"Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study.","volume":"38","author":"Dobyns","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/tx00014a003","article-title":"Mechanism of thyroid peroxidase inhibition by ethylenethiourea.","volume":"3","author":"Doerge","year":"1990","journal-title":"Chem Res Toxicol"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.tox.2005.09.005","article-title":"Studies on the goitrogenic mechanism of action of N,N,N\u2019,N\u2019-tetramethylthiourea.","volume":"217","author":"Freyberger","year":"2006","journal-title":"Toxicology"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/ijc.24545","article-title":"Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity.","volume":"125","author":"Friedman","year":"2009","journal-title":"Int J Cancer"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/thy.2019.0205","article-title":"Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study.","volume":"30","author":"Gronich","year":"2020","journal-title":"Thyroid"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00008469-199411000-00005","article-title":"Thyroid cancer: reproductive factors, previous diseases, drug intake, family history and diet. A case-control study.","volume":"3","author":"Hallquist","year":"1994","journal-title":"Eur J Cancer Prev"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamainternmed.2019.0981","article-title":"Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism.","volume":"179","author":"Kitahara","year":"2019","journal-title":"JAMA Intern Med"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrendo.2017.53","article-title":"Thyroid cancer: the thyroid cancer epidemic - overdiagnosis or a real increase?","volume":"13","author":"La Vecchia","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/ijc.29251","article-title":"Thyroid cancer mortality and incidence: a global overview.","volume":"136","author":"La Vecchia","year":"2015","journal-title":"Int J Cancer"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/ijc.31884","article-title":"Thyroid cancer \u201cepidemic\u201d also occurs in low- and middle-income countries.","volume":"144","author":"Lortet-Tieulent","year":"2019","journal-title":"Int J Cancer"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5271\/sjweh.855","article-title":"Indicators of mancozeb exposure in relation to thyroid cancer and neural tube defects in farmers\u2019 families.","volume":"31","author":"Nordby","year":"2005","journal-title":"Scand J Work Environ Health"},{"key":"R16-20250527","first-page":"1","article-title":"A population-based case-control study of thyroid cancer.","volume":"79","author":"Ron","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.280.4.347","article-title":"Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group.","volume":"280","author":"Ron","year":"1998","journal-title":"JAMA"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/occmed\/26.3.92","article-title":"Ethylene thiourea-a study of possible teratogenicity and thyroid carcinogenicity.","volume":"26","author":"Smith","year":"1976","journal-title":"J Soc Occup Med"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/RLU.0000000000002792","article-title":"Spotlight on the association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism is keeping the highest risk from antithyroid drugs in the blind spot.","volume":"44","author":"Tulchinsky","year":"2019","journal-title":"Clin Nucl Med"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:05:43Z","timestamp":1748361943000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000658","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,22]]}}}